NEW YORK, May 26, 2017 /PRNewswire/ --
On Thursday, the NASDAQ Composite ended the day at 6,205.26, up 0.69%; theDow Jones Industrial Average edged 0.34% higher, to finish at 21,082.95; and the S&P 500 closed at 2,415.07, slightly gaining 0.44%. Gains were broad based as seven out of nine sectors finished the trading session in green. Stock-Callers.com has
Redwood City, California headquartered Avinger Inc.'s stock finished Thursday's session 0.06% lower at $0.36 with a total trading volume of 211,065 shares. The Company's shares are trading 63.50% below their 50-day moving average. Shares of the Company, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have a Relative Strength Index (RSI) of 25.37. AVGR complete research report is just a click away and free at:
On Thursday, shares in Bedford, Ohio headquartered ViewRay Inc. recorded a trading volume of 586,153 shares. The stock ended the session 1.14% lower at $6.08. The Company's shares have advanced 27.73% in the previous three months and 94.25% on an YTD basis. The stock is trading 28.12% above its 200-day moving average. Moreover, shares of ViewRay, which through its subsidiary, ViewRay Technologies, Inc., designs, manufactures, and markets radiation therapy systems, have an RSI of 39.68. The complimentary report on VRAY can be downloaded at:
San Jose, California headquartered Align Technology Inc.'s shares closed the day 1.98% higher at $141.39. The stock recorded a trading volume of 1.88 million shares, which was higher than its three months average volume of 831,110 shares. The Company's shares have gained 18.08% in the last month, 37.42% over the previous three months, and 47.08% on an YTD basis. The stock is trading 14.53% and 38.70% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Align Technology, which designs, manufactures, and markets a system of clear aligner therapy, intra-oral scanners, and computer-aided design and computer-aided manufacturing (CAD/CAM) digital services, have an RSI of 71.41.
On April 28th, 2017, research firm Robert W. Baird upgraded the Company's stock rating from 'Neutral' to 'Outperform' while revising its previous target price from $105 a share to $155 a share. Sign up for your complimentary research report on ALGN at:
Shares in Yokneam Illit, Israel headquartered Syneron Medical Ltd finished 0.46% higher at $10.90. The stock recorded a trading volume of 609,031 shares. The Company's shares have advanced 9.55% in the previous three months and 29.76% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 0.19% and 24.12%, respectively. Furthermore, shares of Syneron Medical, which together with its subsidiaries, researches, develops, manufactures, markets, and sells aesthetic medical products worldwide, have an RSI of 54.92.
On May 12th, 2017, research firm Maxim Group downgraded the Company's stock rating from 'Buy' to 'Hold' while revising its previous target price from $12 a share to $11 a share. Get free access to your research report on ELOS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Strokes occur when blood flow to an area of the brain is cut off. It is imperitive to detect the ...
Bile duct cancer occurs either within the liver or the point where the bile ducts emerge from the ...
Xeroderma pigmentosum is a rare inherited condition marked by extreme sensitivity to sunlight and ...View All